Clinical trials: Movement Disorders
PARKINSON DISEASE (Disorder)
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
- Trial name
- Vista PD (NCT07804615)
- Testing
- VIM0423
- Where
- 30 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Vima Therapeutics
Multiple Sclerosis
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS).
- Trial name
- EXO-MS (NCT07897760)
- Testing
- Electrostimulation suit
- Where
- 2 sites in United States, Germany
- Volunteers
- 100 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Parkinson Disease, Dystonia
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.
- Conditions
- Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
- Trial name
- NCT06553625
- Testing
- Radiofrequency Ablation
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Advanced Parkinson Disease
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
- Trial name
- ELEGANCE (NCT05043103)
- Testing
- Lecigon® based on European Medicines Agency (EMA) SmPC
- Where
- 57 sites in Austria, Belgium and 12 more
- Volunteers
- 312 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Essential Tremor
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is: Is ulixacaltamide a safe and efficacious treatment for patients with essential…
- Trial name
- NCT06087276
- Testing
- 60 mg ulixacaltamide
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Praxis Precision Medicines
Advanced Parkinson Disease
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating…
- Trial name
- SWITCH-ON (NCT07313176)
- Testing
- No Intervention
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 1 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Friedreich's Ataxia (FA)
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA).
- Trial name
- FALCON (NCT07180355)
- Testing
- SGT-212
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Solid Biosciences Inc.
Multiple System Atrophy, Parkinson Variant
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P).
- Trial name
- NCT07825402
- Testing
- ONO-2808
- Volunteers
- 486 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Parkinson Disease
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
- Trial name
- NCT07522606
- Testing
- BIA 28-6156
- Where
- 36 sites in United States, Italy and 3 more
- Sponsor
- Bial R&D Investments, S.A.
Tourette Syndrome
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to [>=] 6 and less than [<] 12 years of age), adolescents (>=12 and <18 years of…
- Trial name
- NCT06021522
- Testing
- Ecopipam
- Where
- 67 sites in United States, Bulgaria and 6 more
- Volunteers
- 150 people
- Sponsor
- Emalex Biosciences Inc.
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Parkinson Disease
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants…
- Trial name
- NCT06602193
- Testing
- BIIB122 225 mg
- Where
- 20 sites in United States, Germany and 2 more
- Volunteers
- 50 people
- Sponsor
- Denali Therapeutics Inc.
Huntington Disease
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
- Trial name
- NCT05541627
- Testing
- AB-1001 Gene Therapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- AskBio France, SAS, a subsidiary of AskBio Inc.
Parkinson's Disease
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who…
- Trial name
- ACTIVATE (NCT05819359)
- Testing
- BIA 28-6156 10 mg, BIA 28-6156 60 mg
- Where
- 95 sites in United States, Canada and 9 more
- Volunteers
- 237 people
- Sponsor
- Bial R&D Investments, S.A.
Huntington Disease
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
- Trial name
- NCT06826612
- Testing
- SPK-10001
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
Movement Disorders, Neurology
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years.
- Conditions
- Movement Disorders, Neurology, Parkinsons Disease
- Trial name
- NCT05539196
- Testing
- Exablate Pallidotomy, Unilateral
- Where
- 5 sites in United States, Japan
- Volunteers
- 60 people
- Sponsor
- InSightec
Parkinson Disease, Tremor
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual…
- Trial name
- NCT05642442
- Testing
- Suvecaltamide
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Jazz Pharmaceuticals
Movement Disorders, Parkinson Disease
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling…
- Conditions
- Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
- Trial name
- ADROIT (NCT04071847)
- Testing
- Deep Brain Stimulation (DBS)
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Parkinson Disease
Open-label Trial in Parkinson's Disease (PD)
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-4 (NCT04760769)
- Testing
- Tavapadon
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 992 people
- Sponsor
- AbbVie
Parkinson Disease
Flexible-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-2 (NCT04223193)
- Testing
- Tavapadon
- Where
- 53 sites in United States, Australia and 11 more
- Volunteers
- 304 people
- Sponsor
- AbbVie